Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville.
Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
JAMA. 2022 Nov 8;328(18):1849-1861. doi: 10.1001/jama.2022.19590.
Hypertension, defined as persistent systolic blood pressure (SBP) at least 130 mm Hg or diastolic BP (DBP) at least 80 mm Hg, affects approximately 116 million adults in the US and more than 1 billion adults worldwide. Hypertension is associated with increased risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and death.
First-line therapy for hypertension is lifestyle modification, including weight loss, healthy dietary pattern that includes low sodium and high potassium intake, physical activity, and moderation or elimination of alcohol consumption. The BP-lowering effects of individual lifestyle components are partially additive and enhance the efficacy of pharmacologic therapy. The decision to initiate antihypertensive medication should be based on the level of BP and the presence of high atherosclerotic CVD risk. First-line drug therapy for hypertension consists of a thiazide or thiazidelike diuretic such as hydrochlorothiazide or chlorthalidone, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker such as enalapril or candesartan, and a calcium channel blocker such as amlodipine and should be titrated according to office and home SBP/DBP levels to achieve in most people an SBP/DBP target (<130/80 mm Hg for adults <65 years and SBP <130 mm Hg in adults ≥65 years). Randomized clinical trials have established the efficacy of BP lowering to reduce the risk of CVD morbidity and mortality. An SBP reduction of 10 mm Hg decreases risk of CVD events by approximately 20% to 30%. Despite the benefits of BP control, only 44% of US adults with hypertension have their SBP/DBP controlled to less than 140/90 mm Hg.
Hypertension affects approximately 116 million adults in the US and more than 1 billion adults worldwide and is a leading cause of CVD morbidity and mortality. First-line therapy for hypertension is lifestyle modification, consisting of weight loss, dietary sodium reduction and potassium supplementation, healthy dietary pattern, physical activity, and limited alcohol consumption. When drug therapy is required, first-line therapies are thiazide or thiazidelike diuretics, angiotensin-converting enzyme inhibitor or angiotensin receptor blockers, and calcium channel blockers.
高血压定义为持续性收缩压(SBP)至少 130mmHg 或舒张压(DBP)至少 80mmHg,影响了大约 1.16 亿美国成年人和超过 10 亿世界范围内的成年人。高血压与心血管疾病(CVD)事件(冠心病、心力衰竭和中风)和死亡的风险增加有关。
高血压的一线治疗是生活方式的改变,包括减肥、健康的饮食模式,包括低钠和高钾摄入、身体活动和适度或消除饮酒。个别生活方式成分的降压效果部分相加,增强了药物治疗的疗效。启动抗高血压药物治疗的决定应基于血压水平和存在高动脉粥样硬化性 CVD 风险。高血压的一线药物治疗包括噻嗪类或噻嗪样利尿剂,如氢氯噻嗪或氯噻酮,血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂,如依那普利或坎地沙坦,以及钙通道阻滞剂,如氨氯地平和应根据办公室和家庭 SBP/DBP 水平进行滴定,以实现大多数人的 SBP/DBP 目标(<130/80mmHg 为年龄<65 岁,SBP <130mmHg 为年龄≥65 岁)。随机临床试验已经证实了降低血压以降低 CVD 发病率和死亡率的疗效。SBP 降低 10mmHg 可使 CVD 事件风险降低约 20%至 30%。尽管血压控制有好处,但只有 44%的美国高血压成年人的 SBP/DBP 控制在 140/90mmHg 以下。
高血压影响了大约 1.16 亿美国成年人和超过 10 亿世界范围内的成年人,是 CVD 发病率和死亡率的主要原因。高血压的一线治疗是生活方式的改变,包括减肥、减少饮食中的钠和增加钾、健康的饮食模式、身体活动和限制饮酒。当需要药物治疗时,一线治疗方法是噻嗪类或噻嗪类利尿剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂以及钙通道阻滞剂。